Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19

Chang Li¹−, Jianfang Ye²−³−, Qijian Chen⁴−, Weihua Hu⁵, Lingling Wang²−³, Yameng Fan⁶, Zhanjin Lu²−³, Jie Chen⁷, Zaishu Chen⁸, Shiyen Chen²−³, Junlu Tong²−³, Wei Xiao¹, Jin Mei⁹, Hongyun Lu¹⁰

¹Department of Cardiology, Hubei No.3 People’s Hospital of Jianghan University, Wuhan 430033, Hubei Province, China
²Department of Endocrinology and Metabolism, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong Province, China
³Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong Province, China
⁴Department of Emergency, The Fifth Hospital in Wuhan, Wuhan 430050, Hubei Province, China
⁵Department of Respiratory, The First Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China
⁶School of Health Sciences, Wuhan University, Wuhan 430071, Hubei Province, China
⁷Department of Gastroenterology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong Province, China
⁸Department of Cardiology, Jiayu People’s Hospital, Jiayu 437200, Hubei Province, China
⁹Central Laboratory, Ningbo First Hospital of Zhejiang University, Ningbo 315010, Zhejiang Province, China
¹⁰Department of Endocrinology and Metabolism, Zhuhai Hospital Affiliated with Jinan University, Zhuhai People’s Hospital, Zhuhai 519000, Guangdong Province, China

*Equal contribution

Correspondence to: Jin Mei, Hongyun Lu; email: tibetcn@aliyun.com, luhongy@mail.sysu.edu.cn
Keywords: COVID-19, lactate dehydrogenase, risk factor, severity, mortality
Received: May 11, 2020 Accepted: July 9, 2020 Published: August 14, 2020

Copyright: Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Early identification of severe patients with coronavirus disease 2019 (COVID-19) is very important for individual treatment. We included 203 patients with COVID-19 by propensity score matching in this retrospective, case-control study. The effects of serum lactate dehydrogenase (LDH) at admission on patients with COVID-19 were evaluated. We found that serum LDH levels had a 58.7% sensitivity and 82.0% specificity, based on a best cut-off of 277.00 U/L, for predicting severe COVID-19. And a cut-off of 359.50 U/L of the serum LDH levels resulted in a 93.8% sensitivity, 88.2% specificity for predicting death of COVID-19. Additionally, logistic regression analysis and Cox proportional hazards model respectively indicated that elevated LDH level was an independent risk factor for the severity (HR: 2.73, 95% CI: 1.25-5.97; P=0.012) and mortality (HR: 40.50, 95% CI: 3.65-449.28; P=0.003) of COVID-19. Therefore, elevated LDH level at admission is an independent risk factor for the severity and mortality of COVID-19. LDH can assist in the early evaluating of COVID-19. Clinicians should pay attention to the serum LDH level at admission for patients with COVID-19.

INTRODUCTION

Since the end of 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19) caused by a novel coronavirus later named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. SARS-CoV-2 is an RNA virus that can be transmitted from person to person, and all people are susceptible to
this infection. At present, COVID-19 has progressed into a pandemic and become a major global health concern. It is reported that most cases are nonsevere type with a good prognosis; however, severe cases may deteriorate rapidly to multiple organ damage, impaired immune function and even death [2]. Therefore, early identification of severe COVID-19 is very important for individual or precise management, including antiviral, organ support and intensive care unit (ICU) care, to improve the prognosis.

Lactate dehydrogenase (LDH) is an intracellular enzyme involved in anaerobic glycolysis that catalyzes the oxidation of pyruvate to lactate [3]. Serum LDH is routinely tested in various diseases clinically. It has been reported that elevated serum LDH levels are associated with poor prognosis in various diseases, especially in tumors and inflammation [4–6]. To date, studies have shown that patients with severe COVID-19 have elevated serum LDH levels [7, 8], but no study has specifically evaluated its effect on the severity and mortality of COVID-19. Therefore, this multicenter retrospective, case-control study aimed to explore whether the serum LDH levels at admission can assist in evaluating the severity and mortality of COVID-19.

RESULTS

Results of propensity score matching and baseline of patients

Sex, age, hypoproteinemia or anemia, tumor history, chronic kidney disease, stroke history, hyperlipidemia, hypertension, diabetes, coronary heart disease, viral hepatitis, smoking and drinking were included as covariates in the logistic regression model of the propensity score matching. We matched 203 patients (128 nonsevere and 75 severe cases) from among 523 patients (424 nonsevere and 99 severe cases) with laboratory confirmed SARS-Cov-2 infection by propensity score matching. The quality assessment of the propensity score matching is shown in Supplementary Figure 1, and the comparison before and after propensity score matching is shown in Table 1. Overall, the results of propensity score matching were satisfactory. After propensity score matching, the difference in covariates between the nonsevere group and the severe group were controlled within no statistical differences (Table 1).

In the current study, 26 (5.0%) out of 523 patients before propensity score matching and 16 (7.9%) out of 203 patients after propensity score matching died of COVID-19. Considering that the patients were not continuously enrolled, we cannot calculate the case fatality rate.

Comparison of laboratory indicators between the nonsevere group and the severe group

We analyzed the levels of laboratory indicators at admission between nonsevere group and severe group. There were significant differences (P<0.05) in the levels of white blood cells (WBCs), neutrophils, lymphocytes, C-reactive protein (CRP), fibrinogen, D-dimer, creatine kinase and LDH between two groups (Figure 1 and Supplementary Table 1). Considering the relationship among laboratory indicators, we conducted Pearson correlation analysis on these laboratory indicators with significant differences. As a result, CRP and LDH exhibited powerful correlations with other indexes (Supplementary Table 2), which suggested that CRP and LDH were significant factors associated with the severity of COVID-19.

Role of the serum LDH in severity and death among COVID-19 cases

We performed ROC curves on the above laboratory indicators with significant differences to assess their value in patients with COVID-19. Lymphocyte counts were the most specific predictor (specificity 94.7%) for severe COVID-19, but with a low sensitivity of 20.3% (Table 2). In contrast, D-dimer had a high sensitivity (86.7%) but a very poor specificity (37.5%) in predicting severe COVID-19. Overall, serum LDH levels had an AUC of 0.76 (95% CI: 0.70 - 0.83) for predicting severe COVID-19, with a 58.7% sensitivity and 82.0% specificity, based on a best cut-off of 277.00 (U/L) (Table 2). However, there seems to be no significant difference between CRP and LDH in predicting severe COVID-19 (Figure 2).

The AUC values of the above indicators, even the CRP and LDH, were not very satisfactory. Therefore, we further analyzed the role of these indicators in predicting the mortality due to COVID-19. Unexpectedly, a cut-off of 91.39 mg/L for serum CRP levels had a sensitivity of 81.3% and a specificity of 88.2% for predicting death in patients with COVID-19 (Table 2). In addition, when the best cut-off of was 359.50 U/L, serum LDH levels had an AUC of 0.92 (95% CI: 0.84 - 0.99) for predicting death due to COVID-19, with a sensitivity of 93.8% and specificity of 88.2% (Table 2). Similarly, there was no significant difference in the ROC curve between CRP and LDH (Figure 3).

Elevated serum LDH as an independent risk factor for the severity of COVID-19

We detected the risk factors for the severity of COVID-19 by univariate and multivariate logistic regression.
Table 1. Baseline of included patients.

|                        | Before matching | After matching | P values |
|------------------------|-----------------|----------------|----------|
|                        | Nonsevere (n=424) | Severe (n=99) |          | Nonsevere (n=128) | Severe (n=75) | P values |
| Female                 | 209(49.3%)      | 39(39.4%)     | 0.096    | 52(40.6%)      | 31(41.3%)     | 1.000    |
| Age                    | 51.45±15.08     | 61.54±13.36   | <0.001   | 57.13±14.55    | 58.49±13.35   | 0.508    |
| Hypoproteinemia or anemia | 24(5.7%)       | 25 (25.3%)    | <0.001   | 13(10.2%)      | 13(17.3%)     | 0.208    |
| Tumor history         | 8(1.9%)         | 1(1.0%)       | 0.861    | 2(1.6%)        | 1(1.3%)       | 1.000    |
| Chronic kidney disease | 10(2.4%)        | 7 (7.1%)      | 0.039    | 6 (4.7%)       | 3(4.0%)       | 1.000    |
| Stroke history        | 8(1.9%)         | 11(11.1%)     | <0.001   | 3(2.3%)        | 1(1.3%)       | 1.000    |
| Hyperlipidemia        | 48(11.3%)       | 8(8.1%)       | 0.448    | 11(8.6%)       | 7(9.3%)       | 1.000    |
| Hypertension          | 82(19.3%)       | 43(43.4%)     | <0.001   | 34(34.4%)      | 25(33.3%)     | 1.000    |
| Diabetes              | 61(14.4%)       | 23(23.2%)     | 0.045    | 32(25.0%)      | 18(24.0%)     | 1.000    |
| Coronary heart disease | 17(4.0%)        | 12(12.1%)     | 0.003    | 7(7.8%)        | 6(8.0%)       | 1.000    |
| Viral hepatitis       | 7(1.7%)         | 1(1.0%)       | 0.99     | 3(2.3%)        | 1(1.3%)       | 1.000    |
| Smoking               | 27(6.4%)        | 13(13.1%)     | 0.008    | 10(7.8%)       | 9(12.0%)      | 0.566    |
| Drinking              | 28(6.6%)        | 16(16.2%)     | 0.002    | 12(9.4%)       | 10(13.3%)     | 0.628    |
| Death                 | 0               | 26(26.3%)     | <0.001   | 0              | 16(21.1%)     | <0.001   |

analysis. Neutrophils were excluded from logical regression analysis because neutrophils and leukocytes were collinear. In univariate analysis, high levels of WBC (HR: 2.32, 95% CI: 1.29, 4.16; P=0.005), CRP (HR: 4.91, 95% CI: 2.61-9.24; P<0.001), neutrophil-to-lymphocyte ratio (HR: 3.51, 95% CI: 1.93-6.39; P<0.001), fibrinogen, D-dimer (HR: 3.26, 95% CI: 1.60-6.64; P=0.001), creatine kinase and LDH (HR: 6.48, 95% CI: 3.40-12.34; P<0.001), and low levels of lymphocytes (HR: 4.53, 95% CI: 1.51-13.53; P=0.007) were risk factors for the severity of COVID-19 (Table 3). Furthermore, we took indicators that were P<0.1 in univariate logistic regression into multivariate logistic regression analysis. Of the 8 indicators, the P value of

![Figure 1. Levels (mean ± SD) of laboratory indicators at admission between the nonsevere group and severe group.](A) white blood cell; (B) neutrophils; (C) lymphocyte; (D) c-reactive protein; (E) fibrinogen; (F) d-dimer; (G) creatine kinase; (H) lactate dehydrogenase. * P<0.05.)
Table 2. Role of laboratory indicators in predicting the severity and death of COVID-19.

| Indicators       | AUC       | Best cut-off * | Sensitivity | Specificity | Sensitivity | Specificity |
|------------------|-----------|----------------|-------------|-------------|-------------|-------------|
| **Predicting severity of COVID-19** |           |                |             |             |             |             |
| WBC              | 0.63±0.04 | 5.65 (×10⁹/L)  | 0.627       | 0.594       |             |             |
| Neutrophils      | 0.66±0.04 | 3.85 (×10⁹/L)  | 0.707       | 0.586       |             |             |
| Lymphocyte       | 0.58±0.04 | 1.72 (×10⁹/L)  | 0.203       | 0.947       |             |             |
| NLR              | 0.68±0.04 | 3.83           | 0.640       | 0.660       |             |             |
| CRP              | 0.73±0.04 | 20.14 (mg/L)   | 0.747       | 0.625       |             |             |
| Fibrinogen       | 0.64±0.04 | 4.79 (g/L)     | 0.533       | 0.758       |             |             |
| D-dimer          | 0.65±0.04 | 0.33 (µg/ml)   | 0.867       | 0.375       |             |             |
| CK               | 0.55±0.04 | 109.50 (U/L)   | 0.347       | 0.812       |             |             |
| LDH              | 0.76±0.04 | 277.00 (U/L)   | 0.587       | 0.820       |             |             |

| Indicators       | AUC       | Best cut-off * | Sensitivity | Specificity |
|------------------|-----------|----------------|-------------|-------------|
| **Predicting death of COVID-19** |           |                |             |             |
| WBC              | 0.78±0.07 | 7.45 (×10⁹/L)  | 0.688       | 0.797       |
| Neutrophils      | 0.82±0.05 | 4.87 (×10⁹/L)  | 0.813       | 0.711       |
| Lymphocyte       | 0.76±0.06 | 0.73 (×10⁹/L)  | 0.759       | 0.750       |
| NLR              | 0.87±0.06 | 7.42           | 0.750       | 0.900       |
| CRP              | 0.89±0.05 | 91.39 (mg/L)   | 0.813       | 0.882       |
| Fibrinogen       | 0.69±0.06 | 3.96 (g/L)     | 0.875       | 0.497       |
| D-dimer          | 0.80±0.06 | 1.09 (µg/ml)   | 0.813       | 0.706       |
| CK               | 0.62±0.08 | 120.50 (U/L)   | 0.438       | 0.818       |
| LDH              | 0.92±0.05 | 359.50 (U/L)   | 0.938       | 0.882       |

* Chosen by maximizing the Youden index. Abbreviations: AUC, area under the curve; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; CRP, C-reactive protein; CK, creatine kinase; LDH, lactic dehydrogenase.

The serum LDH levels was still less than 0.05, which suggested that elevated serum LDH (HR: 2.73, 95% CI: 1.25-5.97; P=0.012) is an independent risk factor for the severity of COVID-19 (Table 3).

**Elevated serum LDH as an independent risk factor for mortality of COVID-19**

We applied the Cox proportional hazards model to evaluate the effect of LDH on the survival time of patients. In univariable Cox regression analysis, male sex (HR: 3.04, 95% CI: 0.87-10.65; P=0.083) and age older than 60 years (HR: 5.88, 95% CI: 1.33-25.90, P=0.019) had a significant effect on the survival time of patients. In addition, elevated serum WBC count (HR: 8.06, 95% CI: 2.8-23.23; P<0.001), neutrophil-to-lymphocyte ratio (HR: 21.11, 95% CI: 6.80-65.51; P<0.001), CRP (HR: 24.06, 95% CI: 6.85-84.50; P<0.001), fibrinogen, D-dimer, CK, LDH (HR: 77.20, 95% CI: 10.20-584.61; P<0.001) and reduced lymphocyte counts were risk factors of mortality (Table 4). We take indicators that were P<0.1 in univariate logistic regression into multivariate logistic regression analysis. We found that the elevated serum LDH (HR: 40.50, 95% CI: 3.35-449.28; P=0.003) remained an independent risk factor for the mortality of COVID-19 (Table 4).

**DISCUSSION**

In this study, we identified that elevated serum LDH level was an independent indicator for predicting severity and mortality in patients with COVID-19 for the first time. Based on ROC analysis, serum LDH
levels at admission had high specificity for predicting the severity of COVID-19 and a satisfactory sensitivity and specificity for predicting death due to COVID-19. Furthermore, logistic regression analysis and Cox proportional hazards model revealed that elevated serum LDH at admission to be an independent risk factor for the severity and mortality of COVID-19.

We regarded sex, age, hypoproteinemia or anemia, tumor history, chronic kidney disease, stroke history, hyperlipidemia, hypertension, diabetes, coronary heart disease, viral hepatitis, smoking and drinking as covariates in the logistic regression model of the propensity score matching, because these covariates may have an impact on the severity and mortality of COVID-19 [9–11]. Autoimmune and inflammatory diseases do have an impact on the severity and mortality of COVID-19. We did not include autoimmune and inflammatory diseases in the logistic regression model of the propensity score matching because there were no patients diagnosed with autoimmune and inflammatory diseases in the enrolled patients. After propensity score matching, the differences in covariables between the nonsevere group and the severe group were controlled at almost the same levels. Controls for confounding factors were the premise of this study, ensuring the reliability of the conclusions.

As suggested by comparison of laboratory indicators, there were significant differences in the levels of WBC, neutrophils, lymphocytes, CRP, fibrinogen, D-dimer, creatine kinase and LDH between nonsevere and severe groups. The differences in these indicators were very similar to those reported by Huang et al. [12]. Notably, LDH showed a powerful correlation with the other indexes by Pearson correlation analysis, which suggested that LDH was a significant factor associated with the severity of patients with COVID-19. When the body experiences acute hypoxia or inflammation, the level of LDH in serum will rise significantly. COVID-19, caused by SARS-Cov-2 infection, mainly involves in the lungs, as well as other tissues and organs [13, 14], leading to hypoxia, thrombogenesis, inflammation and organ injury. Theoretically, elevated serum LDH is an important laboratory indicator for evaluating COVID-19 [15].

In this study, male sex and age older than 60 years old had obvious effects on death due to COVID-19. We found that patients who were aged over 60 years (HR: 5.88, 95% CI: 1.33-25.90, P=0.019) and male (HR: 3.04, 95% CI 0.87-10.65; P=0.083) were more likely to expire, as suggested by the univariate Cox proportional hazards model. This obtained similar general conclusions as previous studies [16, 17]. However, the effect of age and sex on death due to COVID-19 was reduced in multivariate Cox regression because the risk of age and sex was adjusted for other factors.

Elevated serum LDH as an independent risk factor for COVID-19 is the main conclusion of this study. In univariate analysis, high WBC, NLR, CRP, fibrinogen, D-dimer, creatine kinase and LDH, and low lymphocyte were not only risk factors for severity but also risk indicators for death among patients with COVID-19 (Table 3 and Table 4). Additionally, in multivariate analysis, elevated serum LDH remained an independent risk factor for COVID-19 severity and mortality. A previous study [17], which did not mention the influence of LDH on COVID-19, proved that NLR is an

![Figure 3. Receiver operating characteristic (ROC) curve for predicting death (B) of COVID by C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels at admission. LDH: AUC 0.92 ± 0.05, cut-off 359.50 U/L, sensitivity 93.8%, specificity 88.2%. CRP: AUC 0.89 ± 0.05, cut-off 91.39 mg/L, sensitivity 81.3%, specificity 88.2%.](image-url)
There are some limitations in this study that should be noted. Firstly, the number of subjects included is to some extent small which limits the statistical power of this study. Nonetheless, the sample size of this study was sufficient to draw our conclusion. Secondly, on a whole, 16 out of 203 patients died of COVID-19 in this study. Considering the small number of deaths, we performed Cox regression instead of logistic regression to analyze the effect of LDH on COVID-19 mortality. Although the 95% confidence interval of HR is slightly larger, it is enough to ensure that elevated serum LDH is an independent risk indicator for death due to COVID-19. Thirdly, although we have controlled the bias by propensity score matching, multiple potential confounders might not have been fully considered. A small number of patients have taken antiviral drugs, antihypertensive drugs, and antidiabetic drugs prior to admission, the effect of past medical history on the results were not studied.

In conclusion, this study revealed that serum LDH at admission was useful in evaluating the disease severity and in-hospital mortality among patients with COVID-19. Further studies are needed to confirm our findings.

MATERIALS AND METHODS

Study design and participants

We collected data for 523 adult patients admitted to the hospital with laboratory confirmed SARS-Cov-2 infection in 4 designated tertiary hospitals in Hubei.
Province, including 2 in Wuhan city and 2 in cities outside Wuhan, Hubei Province, from January 22, 2020 to March 14, 2020. We divided all these 523 patients into two groups: a severe group (severe type and critical severe type of COVID-19) and a nonsenve group (mild type and moderate type of COVID-19).

Considering that this study is a retrospective study, we used propensity score matching [18] to reduce biases and confounders. Ultimately, 203 patients with COVID-19 (75 patients in the severe group and 128 patients in the nonsenve group) were included.

Inclusion and exclusion criteria

Patients who met all the following criteria were included: (1) ≥18 years old, male or female; (2) laboratory confirmed SARS-Cov-2 infection; (3) complete clinical, laboratory, imaging and outcome data. Patients younger than 18 years old, with incomplete clinical information because of transferring to other designated hospitals were excluded.

Ethical considerations

This study was approved by the Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-sen University (ZDWY2020-K173-1). Written informed consent was waived by the Ethics Committee in consideration of the designated hospital for emerging infectious disease.

Data collection

The data included basic clinical information, diagnosis, comorbidity, and laboratory data at admission including routine blood examination, liver and renal function, myocardial enzyme, blood coagulation, procalcitonin (PCT), CRP and LDH. Additionally, neutrophil-to-lymphocyte ratio (NLR) was calculate. All these data were obtained with a standardized data collection form created by EpiData software (version 3.1). All data were checked by two physicians (Lingling Wang and Jianfang Ye) and a third researcher (Yameng Fan) adjudicated any difference in interpretation between the two primary reviewers.

Diagnosis and classification of COVID-19

COVID-19 was diagnosed and classified according to the newest “Guidelines for the Diagnosis and Treatment of COVID-19 (Trial Version 7)” [19] by the National Health Commission in China (http://www.nhc.gov.cn/). Clinical condition classification criteria are as follows: (1) mild type - clinical symptoms were mild, and no radiological changes; (2) moderate type - fever, respiratory tract or other symptoms, and pneumonia can be seen on imaging; (3) severe type - respiratory rate ≥ 30 times per minute, or the oxygen saturation is lower than 93% at rest state, or the ratio of arterial partial pressure of oxygen (PaO₂) and fraction of inspired oxygen (FiO₂) is lower than 300 mmHg (altitude below 1000 meters), or pulmonary imaging indicate that lung damage deteriorates rapidly within 24 to 48 hours; (4) critical severe type - respiratory failure requiring mechanical ventilation, or signs indicating shock, or multiple organ failure requiring admission to the intensive care unit.

Statistical analysis

Propensity score matching was performed using open source R software (version 3.6.3, Vienna, Austria) based on the “MatchIt” package [20]. The calipers value was set to 0.03, the matching ratio was 1:2, and the matching method was “nearest”. Statistical analysis was performed using IBM SPSS software (version 25.0, Chicago, USA). Statistical charts were generated using GraphPad Prism software (version 8.0, San Diego, USA). The statistical results are presented as mean ± standard deviation. Continuous data were analyzed by the Student’s t-tests, and the Levene test was used to decide homogeneity of variance. The receiver operating characteristic (ROC) curve, sensitivity, specificity and area under the curve (AUC) were measured to evaluate the levels of laboratory indicators in predicting the severity and mortality of COVID-19. Differences between AUCs were detected by the Z-test. All indicators were further tested by univariate and multivariate logistic regression or Cox regression analysis. The hazard ratio (HR) and 95% confidence intervals (95% CI) are shown. P value less than 0.05 was considered statistically significant.

AUTHOR CONTRIBUTIONS

Jianfang Ye designed the idea and drafted the manuscript. Chang Li, Weihua Hu, Zaishu Chen, Wei Xiao, and Qijian Chen provided the clinical data. Jianfang Ye, Lingling Wang, Yameng Fan, Zhanjin Lu, Shiyan Chen, Wei Xiao, Zaishu Chen and Junlu Tong collected the data for this study. Jianfang Ye, Lingling Wang and Yameng Fan checked the data for this study. Jie Chen performed the statistical analysis. Jin Mei and Hongyun Lu guided the entire process of this study and checked the final manuscript.

ACKNOWLEDGMENTS

We acknowledge all health-care workers involved in the diagnosis and treatment of patients in Hubei Province.
CONFLICTS OF INTEREST
All these authors declare no conflicts of interest.

FUNDING
This work was supported by the National Natural Science Foundation of China (grant number 81670815), Guangdong Basic and Applied Basic Research Foundation (grant number 2020A1515010124) and Special Fund for Innovation Strategy of Science and Technology Plan of Guangdong Province (grant number 2019A030317011).

REFERENCES
1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395:507–13. https://doi.org/10.1016/S0140-6736(20)30211-7 PMID: 32007143
2. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020; 201:1380–88. https://doi.org/10.1164/rcrm.202002-0445OC PMID: 32275452
3. Komolafe O, Pereira SP, Davidson BR, Gurusamy KS. Serum c-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis. Cochrane Database Syst Rev. 2017; 4:CD012645. https://doi.org/10.1002/14651858.CD012645 PMID: 28431197
4. Van Wilpe S, Koornstra R, Den Brok M, De Groot JW, Blank C, De Vries J, Gerritsen W, Mehra N. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology. 2020; 9:1731942. https://doi.org/10.1080/2162402X.2020.1731942 PMID: 32158624
5. Pourfathi M, Cereda M, Chatterjee S, Xin Y, Kadlecek S, Duncan I, Hamedani H, Siddiqui S, Profka H, Ehrich J, Ruppert K, Rizi RR. Lung metabolism and inflammation during mechanical ventilation; an imaging approach. Sci Rep. 2018; 8:3525. https://doi.org/10.1038/s41598-018-21901-0 PMID: 29476083
6. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, Makhdoom HQ, Zumla Al, Memish ZA. Epidemiological, demographic, and clinical characteristics of 47 cases of middle east respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013; 13:752–61. https://doi.org/10.1016/S1473-3099(13)70204-4 PMID: 23891402
7. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, Xiong Y, Cheng Z, Gao S, Liang K, Luo M, Chen T, Song S, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020. [Epub ahead of print]. https://doi.org/10.1093/cid/ciaa270 PMID: 32173725
8. Zhang R, Ouyang H, Fu L, Wang S, Han J, Huang K, Jia M, Song Q, Fu Z. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. Eur Radiol. 2020; 30:4417–26. https://doi.org/10.1007/s00330-020-06854-1 PMID: 32279115
9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32170176
10. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; 109:531–38. https://doi.org/10.1007/s00392-020-01626-9 PMID: 32161990
11. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020. [Epub ahead of print]. https://doi.org/10.1002/dmrr.3319 PMID: 32233013
12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497–504. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID: 31986264
13. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CJ, Li L, Chen PY, et al, and China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020; 55:200054. https://doi.org/10.1183/13993003.00547-2020 PMID: 32217650
14. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368:m1091. https://doi.org/10.1136/bmj.m1091 PMID:32217556

15. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z, Wang L, Peng L, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63:364–74. https://doi.org/10.1007/s11427-020-1643-8 PMID:32048163

16. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, Guo GY, Du J, Zheng CL, Zhu Q, Hu M, Li XY, Peng P, Shi HZ. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55:2000524. https://doi.org/10.1183/13993003.00524-2020 PMID:32269088

17. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HH, Luo M, Chen L, Zhao Y. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020; 81:e6–12. https://doi.org/10.1016/j.jinf.2020.04.002 PMID:32283162

18. Duhamel A, Labreuche J, Gronnier C, Mariette C. Statistical tools for propensity score matching. Ann Surg. 2017; 265:E79–80. https://doi.org/10.1097/SLA.0000000000001312 PMID:28486297

19. Ding YQ, Bian XW. [Interpretation of pathological changes for “guidelines for the diagnosis and treatment of COVID-19 by the national health commission (trial version 7)”]. Zhonghua Bing Li Xue Za Zhi. 2020; 49:397–99. https://doi.org/10.3760/cma.j.cn112151-20200318-0021 PMID:32213267

20. Zhang Z. Propensity score method: a non-parametric technique to reduce model dependence. Ann Transl Med. 2017; 5:7. https://doi.org/10.21037/atm.2016.08.57 PMID:28164092
Supplementary Figure 1. Mean differences in covariate balance before and after being adjusted.
## Supplementary Tables

### Supplementary Table 1. Laboratory indicators at admission between the nonsevere group and severe group.

| Indicator          | Nonsevere (n=128) | Severe (n=75) | P value* |
|--------------------|-------------------|---------------|----------|
| WBC (×10⁹/L)      | 5.61±2.16         | 7.17±3.99     | 0.002    |
| Neutrophils (×10⁹/L) | 3.87±1.81         | 5.57±3.73     | <0.001   |
| Lymphocyte (×10⁹/L) | 1.23±0.67         | 1.01±0.45     | 0.014    |
| NLR                | 3.93±3.17         | 7.2±6.41      | <0.001   |
| RBC (×10¹²/L)     | 4.28±0.57         | 4.41±0.56     | 0.113    |
| Platelet(×10⁹/L)  | 224.34±103.38     | 214.08±83.01  | 0.465    |
| Albumin (g/L)     | 37.47±5.77        | 36.12±6.04    | 0.115    |
| TBIL (µmol/L)     | 12.38±7.58        | 13.49±6.89    | 0.250    |
| DBIL (µmol/L)     | 4.42±5.63         | 5.02±3.21     | 0.401    |
| ALT (U/L)         | 35.49±32.48       | 35.61±29.96   | 0.980    |
| AST (U/L)         | 33.54±22.04       | 37.60±22.39   | 0.209    |
| Creatinine(µmol/L) | 83.53±127.53      | 100.44±150.76 | 0.395    |
| TG (mmol/L)       | 1.47±1.11         | 1.43±0.69     | 0.814    |
| TC (mmol/L)       | 4.00±0.99         | 3.83±0.99     | 0.261    |
| UA (µmol/L)       | 272.97±104.19     | 280.56±113.09 | 0.628    |
| PCT (ng/mL)       | 0.20±0.70         | 0.32±0.90     | 0.296    |
| CRP (mg/L)        | 31.84±49.83       | 75.52±73.09   | <0.001   |
| Fibrinogen (g/L)  | 3.99±1.45         | 4.65±1.36     | 0.002    |
| D-dimer (µg/ml)   | 1.45±3.50         | 2.69±5.01     | 0.041    |
| CK (U/L)          | 85.37±80.53       | 148.48±231.03 | 0.025    |
| LDH (U/L)         | 215.23±97.36      | 349.28±177.60 | <0.001   |

*Data were analyzed by Student’s t-tests and Levene test was used to evaluate homogeneity of variance. Abbreviations: WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; RBC, red blood cell; TBIL, total bilirubin; DBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TG, triglyceride; TC, total cholesterol; UA, uric acid; PCT, procalcitonin; CRP, c-reactive protein; CK, creatine kinase; LDH, lactic dehydrogenase.
Supplementary Table 2. Pearson correlation coefficient among levels of laboratory indicators.

|       | WBC   | Neutrophils | Lymphocyte | CRP   | fibrinogen | D-dimer | CK    | LDH   |
|-------|-------|-------------|------------|-------|------------|---------|-------|-------|
| WBC   | 1.00  |             |            |       |            |         |       |       |
| Neutrophils | 0.96** | 1.00        |            |       |            |         |       |       |
| Lymphocyte | 0.22** | -0.01       | 1.00       |       |            |         |       |       |
| CRP   | 0.31** | 0.37**      | -0.37**    | 1.00  |            |         |       |       |
| Fibrinogen | 0.13   | 0.21**      | -0.40**    | 0.54** | 1.00       |         |       |       |
| D-dimer | 0.17*  | 0.23**      | -0.20**    | 0.29** | 0.04       | 1.00    |       |       |
| CK    | 0.02   | 0.00        | -0.08      | 0.20** | 0.05       | -0.07   | 1.00  |       |
| LDH   | 0.34** | 0.41**      | -0.36**    | 0.63** | 0.34**     | 0.33**  | 0.40**| 1.00  |

*There was a statistical difference at the level of P < 0.05. **There was a statistical difference at the level of P < 0.01.

Abbreviations: WBC, white blood cell; CRP, C-reactive protein; CK, creatine kinase; LDH, lactic dehydrogenase.